Cargando…
P1048: PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF RUSFERTIDE IN POLYCYTHEMIA VERA: RESULTS FROM AN ONGOING PHASE 2 STUDY IN PATIENTS WITH ELEVATED HEMATOCRIT VALUES
Autores principales: | Kremyanskaya, Marina, Ping Chew, Lee, Rudraraju, Sneha, Gupta, Suneel, Modi, Nishit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431336/ http://dx.doi.org/10.1097/01.HS9.0000971088.68517.4d |
Ejemplares similares
-
P1016: RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS
por: Kuykendall, Andrew, et al.
Publicado: (2023) -
P1028: PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES HEMATOLOGICAL GAINS AND RESTORES THERAPEUTIC BENEFIT ON REINITIATION IN SUBJECTS WITH POLYCYTHEMIA VERA
por: Kuykendall, A., et al.
Publicado: (2022) -
Polycythemia Vera: Thinking Beyond the Hematocrit
por: Waggoner, Matthew
Publicado: (2023) -
Splenectomy Normalizes Hematocrit in Murine Polycythemia Vera
por: Mo, Jan-Rung, et al.
Publicado: (2009) -
Polycythemia Vera Presenting With Normal Hemoglobin and Hematocrit: A Rare Variant
por: Erdinc, Burak, et al.
Publicado: (2020)